ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,00%
DAX
19 848,77
-0,34%
Brent Oil
73,635
0,48%
Bitcoin
95 409,60
-3,92%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) Actualités

KALV

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KALV
DateHeureSourceTitreSymboleSociété
16/12/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
16/12/202413h00Business WireKalVista Appoints Jeb Ledell as Chief Operating OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
10/12/202403h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202412h30Business WireKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
04/12/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202422h39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202413h00Business WireKalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202421h57Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202418h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KALVKalVista Pharmaceuticals Inc
12/11/202412h30Business WireKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:KALVKalVista Pharmaceuticals Inc
07/11/202420h34Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413h05Business WireKalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionNASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413h00Business WireKalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare TrustNASDAQ:KALVKalVista Pharmaceuticals Inc
28/10/202411h30Business WireKalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyNASDAQ:KALVKalVista Pharmaceuticals Inc
18/10/202412h30Business WireKalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)NASDAQ:KALVKalVista Pharmaceuticals Inc
04/10/202418h29Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema ForumNASDAQ:KALVKalVista Pharmaceuticals Inc
30/09/202412h30Business WireKalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
26/09/202412h30Business WireKalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)NASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202413h00Business WireKalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202412h30Business WireKalVista Appoints Brian Piekos as Chief Financial OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/09/202412h30Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
05/09/202412h30Business WireKalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
03/09/202412h30Business WireKalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
29/08/202412h30Business WireKalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin SymposiumNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202422h17Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202422h13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202422h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KALVKalVista Pharmaceuticals Inc
15/08/202412h30Business WireKalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
22/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KALVKalVista Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:KALV

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
EU
PX4
SBF 120
EU
ACA
Credit Agricole
NASDAQ
NVDA
NVIDIA
EU
PX1
CAC 40
FTSE
UKX
FTSE 100
EU
VIV
Vivendi
NYSE
JPM
JP Morgan Chase
USI
USTECH100
US Tech 100
EU
VK
Vallourec
NYSE
NKE
Nike
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés